Latest Breaking News On - Inflammation immunology - Page 1 : comparemela.com

Anokion SA: Anokion Announces $35 Million Equity Investment from Pfizer

Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development Pfizer Representatives Join Scientific Advisory Board and Board of Directors Anokion SA, a clinical-stage

Agomab Therapeutics NV: Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million

Extension led by Pfizer with participation from new investors Walleye Capital and Asabys Partners as well as existing investors Funding will support next stage of clinical and corporate development

Pfizer Inc.: Pfizer's Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

CHMP also recommends XELJANZ (tofacitinib) approval for the treatment of adults with active ankylosing spondylitis Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's

Pfizer Inc.: XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets